Fractyl Health, Inc. (GUTS)

Company

Fractyl Health, Inc. (GUTS)

StatusFeb 02, 2024
BiotechnologyBiotechnology
Initial Public Offering / IPOInitial Public Offering / IPO

Industry: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

IPO details
Prospectus volume (424B4)IPO closed (8-K)110 m USD7,333,333 shares · 15 USD/share

Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl Health’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. Fractyl Health is based in Burlington, MA. For more information, visit www.fractyl.com.

Chart/Sentiment

Financials

Fractyl Health, Inc. (GUTS)

Latest quarterly filing: 10-Q
Period endRevenue
2025-12-3110-K
0 USD
2024-12-3110-K
93,000 USD
2023-12-3110-K
120,000 USD

Source: SEC Company Facts · USD. Some values may be calculated; please verify them against the official SEC filings.

Scroll to Top